Sharps Technology is a medical device company addressing global issues while engineering a safer future for healthcare providers and people everywhere through compassionate innovation. Sharps’ line of smart safety syringes eliminates accidental needlestick injuries, prevents needle reuse, and reduces wasted vaccines and medicine while retaining the intuitive simplicity of traditional syringes. Sharps Technology aims to be a solution provider for the advancement of future drug delivery systems.

1. CONFIDENTIAL NOT FOR DISTRIBUTION
Smart Safety Syringes for
Pharmaceutical and Healthcare Markets
NASDAQ: STSS
Investor Presentation
June 2022

2. This presentation of Sharps Technology, Inc. (the “Company”) contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform and other securities laws. Words such as “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For
example, the Company is using forward-looking statements when it discusses its vision, the potential of its product, its strategy,
market potential for its products, its paradigm, commercialization of its products, and use of its product candidates and its future
growth. This presentation also contains estimates with respect to the Company’s economics model. Forward-looking statements
are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be
no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from
what is expressed or indicated by the forward-looking statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and uncertainties affecting the Company, the reference is made to the
Company’s reports filed from time to time with the Securities Commission (the “SEC”), including, but not limited to, the risks detailed
in the Company’s preliminary prospectus dated March 30, 2022, filed with the SEC as a part of the Company’s Registration
Statement on Form S-1 (File No. 333-263715), and documents incorporated by reference therein. Forward-looking statements
speak only as of the date the statements are made. The Company Assumes no obligation to update forward-looking statements to
reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-
looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-
looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with
respect to other forward-looking statements.
Forward Looking-Statements
2
CONFIDENTIAL NOT FOR DISTRIBUTION

3. Overview
• Sharps Technology is a medical device and pharmaceutical
packaging company specializing in innovative therapy delivery
systems.
• Sharps is addressing global issues while engineering a
safer future for healthcare providers and people
everywhere.
• Sharps’ product line includes smart safety syringes that eliminate
accidental needlestick injuries, prevents needle reuse, and reduces
wasted vaccines and medicine while retaining the intuitive simplicity
of traditional syringes.
3

4. Long-Term Objective
To become a market
competing solution provider
for therapeutic delivery
systems, addressing multi-
billion-dollar problems with
antiquated solutions
4

6. Sharps Smart Safety Syringes
Solving Two
Billion-Dollar
Problems
6

7. Problem Number 1: Accidental Needlesticks
• Two million accidental needlestick injuries cost
healthcare workers over $1 billion annually
• Sharps Smart Safety Syringes technology can
eliminate the two million needlestick injuries that
happen each year
• Sharps Smart Safety Syringes prevent the
improper reuse of needles and syringes along
with the transfer of blood borne disease, such as
HIV, AIDS, hepatitis B, and hepatitis C.
7

8. Problem Number 2: Waste Space
• Waste space in traditional needles requires
pharma companies to overfill by up to
200% — a waste/cost born by all
• Waste space in a syringe is the amount
which fails to be injected into the patient
and is thrown away with the used syringe
• Eliminating waste space produces more
lifesaving doses of vaccines and drugs
• Hard to manufacture drugs can be made
available more rapidly
8

9. Why Our Technology is Better
• Eliminating waste space produces more
lifesaving doses of vaccines and drugs
• Sharps Provensa smart safety syringes have 10
microliters of dead space and deliver seven
doses from a five-dose vial
• This means Sharps Provensa can produce 700
doses from 100 million vials of the COVID-19
vaccine, compared to the 500 doses a traditional
syringe can produce
• Said another way, Sharps can deliver an
additional 200 million COVID-19 doses, which
would otherwise be discarded
“When you think about the magnitude of the number of
injections being given to respond to the pandemic, this is
not a place where we can afford shortcuts, shortages or
anything short of full safety for patients and healthcare
staff.”
- Lisa Hedman
Senior Advisor, World Health Organization
9

10. Product Pipeline & Matched Market Opportunity
Specialty Syringes - Vial Application
• Types: Auto-Disable Syringes and Safety Syringes
• Applications: Vaccination and Drug Delivery
• End Users: Hospitals, HMOs and Clinics
• Global Smart Syringe Market @ $14 billion USD by 2026 w10.0%+ CAGR
Ready-To-Use - Pre-Filled Syringes
• Types: Polymer and Type I B/S Glass
• Applications: Vaccines, Diabetes, Gene-Therapy
• End Users: Branded Pharma, CMOs and Biologics
• Global Prefilled Syringe Market @ $3.6 billion USD by 2030 w7% CAGR
10
***Confidential. Not for Distribution***

11. P R E S E N T I N G

12. Available in 100%
Silicone Free for
Opthalmics
Ideal for uses with:
HA (hyaluronic acid),
Botox, Embolics
and more…
Lower cost options
Shatter resistance
Weight: 50% less
than glass, thus
reducing shipping
costs
Very low protein
and water
absorption
Ability to design in
ways impossible
with glass
Chemical
resistance is very
good when
compared to glass
Solvent bonded
and ultrasonically
welded
Options for EO,
Gamma and Steam
Autoclave
sterilization
Benefits of Polymer syringes

13. What is a prefilled syringe?
• Single dose units of therapies
• Appealing TCO for customers: Fewer packaging
items (no vials, stoppers, caps, crimps, packaging,
withdrawal needles)
• Easy to use with flexibility on needle attachment
• Pharma Market has shifted to 85% of syringe filling
to prefilled syringes over the past 20 years
• Market:80/20% Glass to Plastic
• New technologies for high speed efficiency filling lines
and flexibility
• ~10x Price of disposable

14. Prefilled Syringes Market

15. • Manufacturing
facility is operating
in Hungary
• Syringe designs with
regulatory approval
received and protected by
proprietary IP
• 40,000 sq. ft.
factory on 250,000
sq. ft. site
• 20-year history of
safety syringe
manufacturing
• ETO capability
Manufacturing Plant — EU
15

16. Research and Development
• Thriving research and development division
• IPO capital is expected to fuel manufacturing
and delivery of 100 million units of the 1ml
and 0.3ml syringes over the next 24 months
• Plant expansion in 2023 increasing capacity
to 350 million units
• Expanding product line, including pre-filled
syringe designs suitable for big pharma
production and specialty market therapeutics,
as well as customized delivery systems
16

17. Active Distribution and Manufacturing Opportunities
***Confidential. Not for Distribution*** 14
• Active project with a major
university for a collaboration to
manufacture our products, here in
the United States. Discussions with
state and federal funding agencies.
• Active project with a major
pharmaceutical company to
produce high value syringes for
them in a joint venture.
• Distribution of our products
throughout the U.S.

18. Investment Highlights
***Confidential. Not for Distribution***
• Recent IPO with capital raise of $15M
• World health organization forecasts 1–2-billion-unit
shortage of the syringes we manufacture
• Smart safety syringes are FDA cleared, approved by Pfizer, and
confirmed by Moderna
• Addressing a $14B global Smart Syringe Market growing at
10.0%+ CAGR
• Addressing a $3.6B global Prefilled Syringe Market growing at
7% CAGR
• Established partnerships — commercialization commencing 2022
• High margin products
18

19. 25 years of healthcare experience,
including drug delivery and syringe
manufacturing. Experience in
Product Innovation and
Management, Global Sales & Key
Account Management, and creating
industry partnerships.
Leadership Team
Former Merck President, Europe,
Canada, Middle East & Africa
and SVP for Merck Vaccines.
P&L responsibility for $10 B in
business.
30 years experience in medical
device sales and distribution
including IV sets, dopler
monitoring, total hip
replacements, surgical stapling
and cold sterilant technology.
19

20. Co-Founder of the company and
inventor of the Sharps ProvensaTM line
of safety syringes. 20+ years of
experience in medical research and
development (R&D) for injection molds
for safety syringe products, and holds
eight patents for safety syringe
products.
Served in various finance roles from
2006 to 2019 in biotech, manufacturing
and distribution, including, CFO of
United Metro Energy; Senior VP of
Finance of Enzo Biochem (NYSE:ENZ).
Prior to 2006, he was an Executive
Director from 2002 to 2006 and a Senior
Manager from 1997 to 2002 at Grant
Thornton LLP.
Dr. Hertz divides his time with a
continuing role as Chief of Vascular
Surgery at Saint Barnabas Medical
Center and Site Director of the
Vascular Fellowship teaching program.
He has extensive consulting experience
for medical devices and previously
served as President of the Vascular
Society of New Jersey.
20
Leadership Team

21. Board of Directors
18

22. Thank You!
For inquiries, please contact:
Sharps Technology
Robert Hayes, CEO
105 Maxess Road, STE 124,
Melville, New York 11747
(631) 574 -4436
RedChip Companies
Investor Relations
Dave Gentry, CEO
dave@redchip.com
407-491-4498
NASDAQ: STSS SharpsTechnology.com